Korro Bio, Inc.

KRRO· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$15.85+10.65%

2026-11-02

Financials

Valuation Metrics

Korro Bio, Inc.'s Market Cap is $233M. At end of 2025 it was $75M. Ranked #2976 of 3,118 in US market (top 95%), #1360 of 1,474 on NASDAQ (top 92%), #245 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$233M	US#2,976/3,118 Sec#245/265
Revenue	$2M	US#2,834/3,118 Sec#183/265
Net Income	$-107M	US—/3,118 Sec—/265
Total Assets	$163M	US#3,012/3,118 Sec#251/265
Net Assets	$103M	US#2,791/3,118 Sec#212/265
Employees	57	US#2,690/3,118 Sec#206/265
Value
P/B	2.26x	US#1,308/3,118 Sec#67/265
P/S	97.95x	US#2,940/3,118 Sec#178/265
FCF Yield	-29.26%	US—/3,118 Sec—/265
Profitability
ROE	-103.31%	US#2,785/3,118 Sec#204/265
ROA	-65.25%	US#3,017/3,118 Sec#234/265
Op. Margin	-3176.57%	US#2,820/3,118 Sec#171/265
Revenue Growth	-62.08%	US#2,701/3,118 Sec#162/265
Financial Health
Debt Ratio	58.34%	US#656/3,118 Sec#142/265
Total Debt	$42M	US#2,623/3,118 Sec#159/265
FCF	$-68M	US#2,569/3,118 Sec#123/265
Cash	$25M	US#2,800/3,118 Sec#249/265
Current Ratio	9.55x	US#259/3,118 Sec#80/265
Performance
1Y Return	-61.27%	US#2,974/3,118 Sec#247/265
1M Return	64.37%	US#23/3,118 Sec#6/265
From 52W High	-58.76%	US#2,923/3,118 Sec#232/265
1Y MDD	-84.40%	US#3,083/3,118 Sec#255/265
Trading
Volume	203,133 shares	US#2,802/3,118 Sec#257/265
Trading Value	$3M	US#2,899/3,118 Sec#243/265
Per Share
EPS	$-7.24	US—/3,118 Sec—/265
BPS	$7.01	US#2,082/3,118 Sec#98/265

Company Info

CEO Ram Aiyar

Employees 57

HQ Cambridge, US

Website https://www.korrobio.com

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.